Novartis Institutes for BioMedical Research, Emeryville, California, USA.
Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0092122. doi: 10.1128/aac.00921-22. Epub 2022 Nov 30.
CUO246, a novel DNA gyrase/topoisomerase IV inhibitor, is active against a broad range of Gram-positive, fastidious Gram-negative, and atypical bacterial pathogens and retains activity against quinolone-resistant strains in circulation. The frequency of selection for single step mutants of wild-type S. aureus with reduced susceptibility to CUO246 was <4.64 × 10 at 4× and 8× MIC and remained low when using an isogenic QRDR mutant (<5.24 × 10 at 4× and 8× MIC). Biochemical assays indicated that CUO246 had potent inhibitory activity against both DNA gyrase (GyrAB) and topoisomerase IV (ParCE). Furthermore, CUO246 showed rapid bactericidal activity in time-kill assays and potent efficacy against S. aureus in a neutropenic murine thigh infection model. These results suggest that CUO246 may be useful in treating infections by various causative agents of acute skin and skin structure infections, respiratory tract infections, and sexually transmitted infections.
CUO246 是一种新型的 DNA 拓扑异构酶/拓扑异构酶 IV 抑制剂,对广泛的革兰氏阳性、苛养革兰氏阴性和非典型细菌病原体具有活性,并保留对循环中喹诺酮耐药株的活性。对野生型金黄色葡萄球菌的单步突变体的选择频率较低,对 CUO246 的敏感性降低,在 4×和 8×MIC 时<4.64×10,当使用同源 QRDR 突变体时,频率仍然较低(<5.24×10 在 4×和 8×MIC)。生化分析表明,CUO246 对 DNA 拓扑异构酶(GyrAB)和拓扑异构酶 IV(ParCE)均具有很强的抑制活性。此外,CUO246 在时间杀伤试验中表现出快速杀菌活性,并在中性粒细胞减少症小鼠大腿感染模型中对金黄色葡萄球菌表现出强大的疗效。这些结果表明,CUO246 可能对治疗各种急性皮肤和皮肤结构感染、呼吸道感染和性传播感染的病原体引起的感染有用。